Glutaminylarginine

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Glutaminylarginine
• 英文别名: 5-(diaminomethylideneamino)-2-[(2,5-diamino-5-oxopentanoyl)amino]pentanoic acid
• 化学式: C₁₁H₂₂N₆O₄
• 分子量: 302.33
• InChiKey: OPINTGHFESTVAX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -5.6
• 重原子数：
  21
• 可旋转键数：
  10
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  200
• 氢给体数：
  6
• 氢受体数：
  6

文献信息

• Compositions to improve tic disorders
  申请人：Ozeki Makoto

  公开号：US20060217321A1

  公开（公告）日：2006-09-28

  Tic disorders can be improved by administering theanine, an amino acid that crosses the blood-brain barrier, or a dipeptide consisting of theanine and a different amino acid. In addition, these compositions can be added to foods and drinks or pharmaceuticals.

  滴状障碍可以通过给予茶氨酸改善，这是一种可以穿过血脑屏障的氨基酸，或者是由茶氨酸和另一种氨基酸组成的二肽。此外，这些组合物可以添加到食品和饮料或药品中。
• Nutrient compositions containing peptides
  申请人：CLINTEC NUTRITION COMPANY

  公开号：EP0457314A1

  公开（公告）日：1991-11-21

  Nutrient compositions comprise an aqueous solution of at least one dipeptide with an N-terminal amino acid selected from glutamine, aspargine, tyrosine, tryptophan, and aspargine. The C-terminal amino acid is alanine, glycine, tryptophan, arginine, proline or serine. The nutritional compositions contain from about 0.1 to 25.0 percent by weight of oligopeptides, preferably about 0.5 to 5.0 percent by weight.

  营养组合物包含至少一种二肽的水溶液，其 N 端氨基酸选自谷氨酰胺、天门冬氨酸、酪氨酸、色氨酸和天门冬氨酸。 C 端氨基酸为丙氨酸、甘氨酸、色氨酸、精氨酸、脯氨酸或丝氨酸。营养组合物含有约 0.1%至 25.0%（按重量计）的低聚肽，最好是约 0.5%至 5.0%（按重量计）。
• Method of preparing botulinum neurotoxin type A light chain
  申请人：Johnson A. Eric

  公开号：US20060258847A1

  公开（公告）日：2006-11-16

  The present invention provides a preparation of botulinum toxin light chain type A or E, wherein the preparation is both catalytically active and soluble. Preferably, the preparation consists essentially of amino acid residues 1 through 425 of the botulinum toxin light chain type A. A method of screening inhibitors is also provided, wherein the method comprises exposing a test inhibitor to the preparation of botulinum toxin light chain type A and evaluating the biological activity of the preparation. In another embodiment, a method of providing a catalytically active, soluble preparation of botulinum toxin light chain, type A is provided, wherein the method comprises obtaining an expression vector comprising a DNA sequence encoding amino acid residues 1 - 425 and expressing a polypeptide.

  本发明提供了一种 A 型或 E 型肉毒毒素轻链制剂，其中该制剂具有催化活性和可溶性。优选地，制剂主要由氨基酸残基组成 1 至 425 还提供了一种筛选抑制剂的方法，其中该方法包括将测试抑制剂暴露于肉毒杆菌毒素轻链 A 型的制剂中，并评估该制剂的生物活性。在另一个实施方案中，提供了一种提供具有催化活性的可溶性 A 型肉毒毒素轻链制剂的方法，其中该方法包括获得表达载体，该载体包含编码氨基酸残基的 DNA 序列 1 - 425 并表达多肽。
• Method of Preparing Botulinum Neurotoxin Type E Light Chain
  申请人：Johnson Eric A.

  公开号：US20090182123A1

  公开（公告）日：2009-07-16

  The present invention provides a preparation of botulinum toxin light chain type A or E, wherein the preparation is both catalytically active and soluble. Preferably, the preparation consists essentially of amino acid residues 1 through 425 of the botulinum toxin light chain type A. A method of screening inhibitors is also provided, wherein the method comprises exposing a test inhibitor to the preparation of botulinum toxin light chain type A and evaluating the biological activity of the preparation. In another embodiment, a method of providing a catalytically active, soluble preparation of botulinum toxin light chain, type A is provided, wherein the method comprises obtaining an expression vector comprising a DNA sequence encoding amino acid residues 1-425 and expressing a polypeptide.
• US5965699A
  申请人：——

  公开号：US5965699A

  公开（公告）日：1999-10-12